{"url_path":"/sec/bfnh/10-q/2026/item-5","section_key":"item-5","section_title":"Item 5 OTHER INFORMATION.**","topic":"sec","document":{"doc_type":"10-Q","doc_date":"2026-05-19","source_url":"https://www.sec.gov/Archives/edgar/data/1310488/0001091818-26-000077-index.html","accession_number":"0001091818-26-000077","cik":"0001310488","ticker":"BFNH","issuer_name":"BIOFORCE NANOSCIENCES HOLDINGS, INC.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1310488/0001091818-26-000077-index.html","primary_entity_key":"0001310488","primary_entity_name":"BIOFORCE NANOSCIENCES HOLDINGS, INC."},"word_count":131,"has_tables":true,"body_markdown":"**ITEM 5. OTHER INFORMATION.**\n\n \n\nSubsequent to the close of the March 31, 2026 quarter, in April 2026,\nthe board of directors received a conversion notice from Nauri Dean Ahmad from whom the Company had borrowed $10,000. In accordance with\nthe loan document between Mr. Ahmad and the Company, Mr Ahmad was entitled to $11,000 in principal and interest repayment and 3,000 restricted\nshares as a premium for giving the Company a loan.  Mr. Ahmad received 24,250 shares of restricted 144 common stock on April 16,\n2026, based on the closing price on that day.\n\n \n\nSubsequent to the close of the March 31, 2026 quarter, on April 15,\n2026, Merle Ferguson, a director of the Company sold his controlling stock interest, approximately 80%, in a private transaction to Nexus\nCapital Investments, Inc."}